Nemtabrutinib

Nemtabrutinib (MK-1026) is Merck's oral, non-covalent BTK inhibitor, now in Phase 3 for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) without TP53 aberrations [2,3]. BTK is a signaling protein inside B cells that drives proliferation when the B-cell receptor fires; blocking it shuts CLL down. The class is saturated: AbbVie/J&J's Imbruvica, AstraZeneca's Calquence, and BeiGene's Brukinsa own the covalent BTKi market, and Lilly's Jaypirca beat Merck to the non-covalent niche with a 2023 accelerated approval in relapsed/refractory CLL [7]. Worse for Merck, pirtobrutinib's BRUIN CLL-313 readout at ASH 2025 showed an HR of 0.199 versus bendamustine-rituximab in 1L CLL [10], and BRUIN CLL-314 matched ibrutinib in BTKi-naive patients [11] — Jaypirca is on a credible glide path to 1L CLL approval before nemtabrutinib's Phase 3 reads out. Merck has no real foothold in CLL today; nemtabrutinib is the bid to change that. The key question is whether a reversible binder arriving third or fourth into 1L can carve commercial space against acalabrutinib and a likely-approved Jaypirca — a high bar that none of Merck's competitors had to clear when they launched.

Novel compound, never approved anywhere. Originated as ARQ 531 at ArQule, acquired by Merck in 2019. The Phase 3 program has at least two registrational studies running. BELLWAVE-008 (NCT05624554) randomizes untreated CLL/SLL patients without TP53 aberrations against investigator's choice of FCR (fludarabine + cyclophosphamide + rituximab) or BR (bendamustine + rituximab) chemoimmunotherapy, with PFS superiority as the primary endpoint [2]. BELLWAVE-011 (NCT06136559) is the more aggressive head-to-head: nemtabrutinib versus investigator's choice of ibrutinib or acalabrutinib in first-line CLL/SLL, with a 1,200-patient enrollment target and ORR by blinded independent central review as the primary endpoint [3]. A large Phase 2 (MK-1026-003, NCT04728893, n=490) continues to enroll across heme malignancies and supplies safety and efficacy data across subtypes [4]. First-in-human Phase 1/2 data published in Cancer Discovery in 2024 showed activity in heavily pretreated CLL — including patients with C481S mutations that knock out covalent BTK inhibitors [1]. Population PK modeling published in 2026 indicates dosing is well characterized for the registrational program [5]. No FDA breakthrough therapy or fast track designation has been publicly disclosed for the CLL indication. Merck has not formally guided readout timing; given enrollment status and the likely need for mature PFS data, a primary analysis in 2027–2029 is the realistic window.

BTK (Bruton's tyrosine kinase) is a signaling enzyme inside B cells. When the B-cell receptor on the surface engages antigen, BTK switches on and passes the signal downstream, telling the cell to survive and divide. In CLL, this pathway is stuck on, fueling the leukemia. Block BTK and you starve CLL cells of the survival signal — confirmed clinically by ibrutinib (Imbruvica), which transformed CLL outcomes after its 2014 approval [7]. The catch: ibrutinib, acalabrutinib, and zanubrutinib are all covalent inhibitors that latch onto a specific cysteine (C481) inside the BTK active site. CLL cells under selective pressure mutate that cysteine to serine (C481S), and the drug can no longer grip the protein. C481S is the most common resistance mechanism for covalent BTK inhibitors. Nemtabrutinib binds non-covalently. It sits in the BTK active site without forming a permanent bond, so it doesn't depend on C481. It retains activity against C481S and several other resistance mutations [1]. This is the same playbook as Lilly's pirtobrutinib (Jaypirca), which validated the non-covalent class with FDA approval for relapsed/refractory CLL in late 2023 [7]. BTK biology is well validated: four approved covalent inhibitors, one approved non-covalent inhibitor, consistent activity across multiple B-cell malignancies, and supporting evidence from BTK loss-of-function genetics in X-linked agammaglobulinemia. BTK inhibition works — that's settled. The real question for nemtabrutinib is whether this specific molecule can carve out commercial space against pirtobrutinib in the non-covalent niche and against acalabrutinib in first-line CLL. CNS penetration data — increasingly relevant as the class is studied in primary and secondary CNS lymphoma — has not been publicly disclosed for nemtabrutinib.

BELLWAVE-008 (NCT05624554) and BELLWAVE-011 (NCT06136559) test fundamentally different questions and should not be conflated. BELLWAVE-008 randomizes untreated, TP53-intact CLL/SLL patients against investigator's choice of FCR or BR chemoimmunotherapy, with PFS superiority as the primary endpoint [2]. BELLWAVE-011 randomizes 1,200 untreated CLL/SLL patients against investigator's choice of ibrutinib or acalabrutinib, with ORR by BICR as the primary endpoint [3]. BELLWAVE-008 asks whether nemtabrutinib beats chemo — a low bar that BTKi class data already strongly predicts. BELLWAVE-011 asks whether it beats established BTKi standard of care — a much higher bar and the trial that defines the commercial story. The TP53 exclusion in BELLWAVE-008 is an ethical and regulatory necessity, not a design choice that broadens the population. TP53-aberrant CLL patients respond so poorly to chemoimmunotherapy that randomizing them to FCR/BR would be unethical; they are already routed straight to BTKi or venetoclax-based therapy. Excluding them narrows BELLWAVE-008 to the shrinking subset of fit-for-chemo 1L patients — a population whose standard of care is increasingly venetoclax + obinutuzumab (CLL14 regimen, fixed-duration) or a BTKi rather than chemo. A chemo-controlled win in 2027–2028 will look dated against contemporary practice. BELLWAVE-011's ORR-primary design is unusual for a 1,200-patient 1L CLL trial — PFS is the conventional regulatory endpoint for BTKi class trials. Merck has not publicly disclosed FDA alignment on this endpoint choice or whether PFS is a co-primary or key secondary; this is an open question for investors. ORR primaries can hit early but produce a thin commercial claim if PFS doesn't separate. Phase 2 NCT04728893 (MK-1026-003) continues to enroll up to 490 patients across heme malignancies, generating supporting data for indication expansion [4]. A separate Phase 1 drug-drug interaction study with diltiazem (NCT07232589) confirms CYP3A4 metabolism — relevant for the elderly CLL population on cardiac comedications. The real concern is comparator strength. Acalabrutinib in 1L CLL produces multi-year PFS rates in the 60–70% range at 5–7 years; nemtabrutinib has to match or beat that on long follow-up.

Our model estimates a 30% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 57%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results, a randomized design, and a comparator/control arm. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

**Efficacy risk:** The 1L CLL bar is high. Acalabrutinib delivers multi-year PFS in TP53-intact patients, so matching it requires long follow-up that extends trial cost and exposes nemtabrutinib to any late safety signals. ORR as the BELLWAVE-011 primary endpoint risks an early-looking-good readout that fails to translate into commercially meaningful PFS gains. **Safety risk:** Class-wide BTK inhibitor toxicity includes atrial fibrillation, hypertension, bleeding, and infections. Acalabrutinib and zanubrutinib already differentiated from ibrutinib on cardiac safety. Phase 1/2 data for nemtabrutinib showed a manageable profile but with hypertension and infection signals consistent with the class [1]. The diltiazem drug-drug interaction study (NCT07232589) flags CYP3A4 metabolism, which matters in elderly CLL patients on cardiac comedications. **Competitive risk:** This is the real problem, and it has gotten materially worse since ASH 2025. Pirtobrutinib (Jaypirca) is no longer a r/r-only competitor. BRUIN CLL-313 (n=282) reported pirtobrutinib versus BR in 1L CLL with an HR of 0.199 (95% CI 0.107–0.367, p<0.0001) — an ~80% reduction in progression-or-death risk and a 24-month PFS of 93.4% vs 70.7% [10]. BRUIN CLL-314 matched pirtobrutinib to ibrutinib in BTKi-naive patients with an early PFS advantage [11]. Pirtobrutinib is on a credible path to 1L CLL approval — potentially years before nemtabrutinib's Phase 3 reads out. Merck would then enter as the third or fourth BTKi in 1L, behind acalabrutinib, zanubrutinib, and an established Jaypirca with real-world data and hematologist familiarity. The covalent BTKi market remains saturated: AbbVie's Imbruvica franchise (~$3B+ in 2024) [9], AstraZeneca's Calquence (~$3.5B in 2024) [8], BeiGene's Brukinsa (~$2.5B+ in 2024). Fixed-duration venetoclax + obinutuzumab (CLL14 regimen) further compresses indefinite-BTKi share among oncologists who prefer time-limited therapy. **Execution risk:** Active-comparator enrollment is slower than placebo. A 1,200-patient trial against ibrutinib or acalabrutinib is a multi-year commitment, and Merck's CLL field infrastructure is thin compared to AbbVie and AstraZeneca, which have long-standing relationships with community hematologists. **Commercial risk:** Payers will demand head-to-head efficacy advantages or clear safety wins. 'Me-too non-covalent' pricing will be punished, and the addressable market is shrinking as Jaypirca takes 1L share ahead of nemtabrutinib's readout.

Worth watching, eyes open, but the competitive window has tightened. Merck has the resources to run this program properly and the strategic motivation — Keytruda contributed ~$29.5B of Merck's $64.2B 2024 revenue [6], and the U.S. compound patent expires in December 2028 [6], with biosimilar erosion expected within 2–3 years of cliff. Heme oncology assets like nemtabrutinib are part of a post-Keytruda diversification imperative, not opportunistic portfolio expansion. Merck's CLL franchise today is functionally zero, so any successful launch generates incremental revenue — but the addressable share is shrinking as pirtobrutinib looks set to claim 1L territory ahead of nemtabrutinib's Phase 3 readout. The signal moment: a BELLWAVE-011 readout showing comparable or better PFS than acalabrutinib in 1L combined with a meaningfully cleaner cardiac safety profile. Anything less and Merck is launching the third or fourth-in-class BTKi into a market that already has a non-covalent option in Jaypirca with strong 1L data. The drug doesn't need to be revolutionary — it needs to be at least non-inferior to acalabrutinib with a differentiated tolerability story, and Merck needs to disclose FDA alignment on the BELLWAVE-011 ORR primary so investors can size regulatory risk. Check back at three points: (1) any ASH or EHA presentations from the Phase 2 MK-1026-003 — particularly subgroup data in C481S and double-resistant patients; (2) BELLWAVE-011 enrollment completion timing on clinicaltrials.gov; (3) Merck Q3/Q4 earnings calls for commercial commitment signals and any disclosure on FDA endpoint alignment. The completed diltiazem DDI study suggests Merck is doing the regulatory groundwork seriously — a positive operational signal, not a clinical one. Realistic registrational decision window: 2027–2029.